Drug intelligence / Profile preview

PROfortil

Development stage: Unknown
Lead developer: Lenus Pharma
Modality: Small Molecules
Administration: Oral

Overview

PROfortil is a patented, multi-ingredient nutraceutical specifically designed to improve male fertility by optimizing sperm quality. Developed by Lenus Pharma and distributed in Canada by Red Leaf Medical, the formulation includes L-carnitine, L-arginine, Coenzyme Q10, Vitamin E, Zinc, Folic acid, Glutathione, and Selenium. These components work synergistically to enhance sperm count, motility, and morphology while protecting sperm DNA from oxidative damage. It is indicated for men with subfertility or those undergoing assisted reproductive technologies (ART) to improve conception outcomes. The product is approved by Health Canada as a natural health product for supporting male reproductive health.

Brand names: PROfortil

Targets

DNAGPX4 (Glutathione peroxidase 4)

Beyond the preview

Go deeper on PROfortil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PROfortil.

Explore the full profile